Next Article in Journal
Alemtuzumab in Chronic Lymphocytic Leukemia
Previous Article in Journal
Cancer Symptom Control Trials: How May We Advance This Field?
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Article

The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

by 1, 1, 1 and 2,* on behalf of the MAP.3 Consortium
1
National Cancer Institute of Canada Clinical Trials Group, Queen’s University, Kingston, ON, Canada
2
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2007, 14(3), 89-96; https://doi.org/10.3747/co.2007.117
Received: 1 March 2007 / Revised: 3 April 2007 / Accepted: 1 May 2007 / Published: 1 June 2007
Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has developed a randomized phase III study to determine the efficacy of an AI (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The NCIC CTG MAP.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the AIS, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene.
Keywords: aromatase inhibitors; breast cancer risk reduction; chemoprevention aromatase inhibitors; breast cancer risk reduction; chemoprevention
MDPI and ACS Style

Richardson, H.; Johnston, D.; Pater, J.; Goss, P., on behalf of the MAP.3 Consortium. The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial. Curr. Oncol. 2007, 14, 89-96. https://doi.org/10.3747/co.2007.117

AMA Style

Richardson H, Johnston D, Pater J, Goss P on behalf of the MAP.3 Consortium. The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial. Current Oncology. 2007; 14(3):89-96. https://doi.org/10.3747/co.2007.117

Chicago/Turabian Style

Richardson, H., D. Johnston, J. Pater, and P. Goss on behalf of the MAP.3 Consortium. 2007. "The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial" Current Oncology 14, no. 3: 89-96. https://doi.org/10.3747/co.2007.117

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop